Hui R, Özgüroğlu M, Villegas A, et al. - Given that the primary endpoints of progression-free survival and overall survival were improved by durvalumab vs placebo, with similar safety, in patients with unresectable, stage III non-small-cell lung cancer, in the ongoing, phase 3 PACIFIC trial, researchers assessed patient-reported outcomes (PROs), one of the secondary endpoints, in this present study. Using randomization (2:1), they administered 10 mg/kg intravenous durvalumab or matching placebo 1–42 days following concurrent chemoradiotherapy, then every 2 weeks up to 12 months, to the patients. With both treatments, the prespecified longitudinal PROs of interest, cough, dyspnoea, fatigue, appetite loss, physical functioning, and global health status or quality of life continued to be stable between baseline and 12 months, with no clinically important alterations from baseline. Overall, durvalumab has the ability to provide a clinical benefit without compromising PROs. This finding is notable since the prior standard of care was observation alone, with no presumed detriment to PROs.